Tumours with irreversible MHC loss exhibit intrinsic resistance to CD8+ T cell‐based immunotherapies, including PD‐1/PD‐L1 and CTLA‐4 blockade and adoptive T cell therapies. The gene discussed is CD8A; the disease is neoplasm.